Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

approvals and late-breaking clinical data that signal continued momentum in kidney disease therapeutics.

The Agency expanded treatment options across immune-mediated and rare kidney diseases, including a new subcutaneous formulation of anifrolumab (Saphnelo) for systemic lupus erythematosus and the landmark approval of sparsentan (Filspari) as the first indicated therapy for

 focal segmental glomerulosclerosis (FSGS)

Meanwhile, results from the phase 3 APPLAUSE-IgAN trial presented at the 

2026 demonstrated clinically meaningful slowing of kidney function decline with iptacopan (Fabhalta), reinforcing the growing role of targeted therapies in glomerular disease.

Alongside these advances, expert-driven discussions on APOL1-mediated kidney disease and emerging combination strategies, including atrasentan layered onto SGLT2 inhibition, underscored a field rapidly advancing toward precision medicine.

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data!

Anifrolumab (Saphnelo) Wins FDA Approval for Subcutaneous Self-Administration in SLE

On April 27, 2026, the FDA approved anifrolumab for once-weekly subcutaneous self-administration for use in adult patients with moderate to severe systemic lupus erythematosus receiving standard therapy/

The approval was based on results from a multicenter, randomized, double-blind, placebo-controlled phase 3 TULIP-SC trial evaluating subcutaneous anifrolumab versus placebo in 367 adults aged 18 to 70 years. According to AstraZeneca, subcutaneous anifrolumab achieved a statistically significant and clinically meaningful reduction in disease activity compared with placebo on this endpoint.

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

On April 13, 2026, the FDA granted full approval to sparsenten to treat FSGS. This decision signaled a historic milestone for the rare kidney disease as the first approved therapeutic option for a historically off-label, supportive-care-dominated disease area.

Supported by data from 2 of the largest head-to-head interventional studies in adult and pediatric patients with FSGS, the phase 3 

, sparsentan’s mechanism combines dual endothelin A and angiotensin II type 1 receptor blockade to address podocyte injury without immunosuppression.

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

APPLAUSE-IgAN: Iptacopan (Fabhalta) Exhibits 49.3% Slower eGFR Decline in IgAN Patients Than Placebo

Iptacopan demonstrated a 49.3% slower rate of estimated glomerular filtration rate (eGFR) decline compared to placebo. The final 2-year results from the phase 3 APPLAUSE-IgAN trial. were announced by Novartis and presented as late-breaking data at the 2026 WCN.

Additional findings included a 43% reduction in the likelihood of composite kidney failure events and 40.7% of iptacopan-treated patients achieving target proteinuria, compared with 23.7% in the placebo group.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

For the third annual APOL1-mediated kidney disease day, HCPLive put together a feature including perspectives from 5 experts in the nephrology field. Topics included the problem of misdiagnosis, unpredictable progression, and uneven access to genetic insight, while considering the emergence of targeted therapies.

Kidney Compass: ASSIST Trial Shows Atrasentan Benefit on Top of SGLT2 Inhibitors

5 Nephrology Headlines You Missed in April 2026

hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS,

discussed several concepts presented at WCN 2026, including the phase 2 ASSIST trial, which evaluated the efficacy and safety of atrasentan in combination with SGLT2 inhibitors.

Articles

April 2026 delivered meaningful inflection points in kidney therapeutics, spanning immune-mediated, rare, and complement-driven glomerular diseases. FDA action enabled once-weekly subcutaneous self-administration of anifrolumab for moderate-to-severe SLE, potentially broadening outpatient usability. Sparsentan received full approval as the first indicated treatment for FSGS, supported by DUPLEX and DUET and leveraging dual ETA/AT1 blockade without immunosuppression. Late-breaking APPLAUSE-IgAN results showed iptacopan slowed eGFR decline and reduced kidney-failure events, underscoring accelerating precision strategies.

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data. 

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

FDA News

Videos

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

, in Las Vegas, Nevada, brought together a number of key clinicians to share updates and advancements in everything from obesity and diabetes to 

. Trials like CAHtalyst Adult and discussions on topics like GLP-1s in 

 took center stage over the 3-day meeting.

With all of the new data and key perspectives being shared throughout the conference, the editorial team at 

 has collected 5 of the most impactful headlines to come out of AACE 2026. Catch up on any major data you may have missed during the conference below:


Reemphasizing Nutrition and Diet in Managing Chronic Endocrine Disease, With Jeffrey Mechanick, MD


Jeffrey Mechanick, MD, medical director of the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital, discusses the importance of employing nutritional goals in managing obesity and preventing additional endocrine diseases. Mechanick highlights the interplay between the metabolic system and the exposome, noting that nutrition is far more than simply diet and exercise – and every aspect has an impact on endocrine health.


Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD


2-year data from the CAHtalyst Adult study have shown substantial and sustained reductions in glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) when treated with crinecerfont. In addition to these positive results, Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan, discusses the substantial retention observed throughout the open-label extension.


Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD


Although the risks of iodine deficiency are well-documented, excess iodine also poses substantial risk to the thyroid – and can be caused through unexpected sources, including common micronutrient supplements and iodized salt. To address this, Shashank Joshi, MD, a consultant endocrinologist at Lilavati Hospital and Joshi Clinic, highlights a narrow iodine window that clinicians should target, given the thyroid’s intolerance of extremes in either direction.


Beyond Insulin: Evaluating GLP-1 RAs as Adjunctive Therapy in Type 1 Diabetes, With Viral Shah, MD


Although T1D treatment is largely reliant on insulin therapy, a significant proportion of patients fail to achieve time in range >70%, driven in part by rising rates of obesity. To this end, Viral Shah, MD, a professor of medicine in the division of endocrinology & metabolism and director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic Diseases at Indiana University, discusses the potential of implementing GLP-1 medications in T1D. Their well-documented efficacy in reducing excess adiposity, coupled with their potentially beneficial effects for cardiovascular health, make them an attractive potential adjunct to existing insulin therapy.


Diabetes Dialogue: Nutrition, Medication, and Treatment in Obesity With Elizabeth Bauer, MD


In a special on-site episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, meet with Elizabeth Bauer, MD, to discuss her “Year in Review” presentation at AACE. AACE’s updated obesity algorithm, emerging obesity pharmacotherapies, and the management of disease and medication side effects take center stage as Bauer covers the full scope of obesity in both the clinical and patient setting.

AACE 2026 emphasized integrated endocrine care spanning nutrition, obesity therapeutics, thyroid micronutrient management, and adrenal and diabetes innovations. Nutrition was framed as a targeted metabolic intervention influenced by the exposome, extending beyond diet and exercise. In classic CAH, 2-year CAHtalyst Adult data supported sustained glucocorticoid dose reductions with crinecerfont alongside strong open-label extension retention. Thyroid discussions stressed a narrow therapeutic window for iodine, with both deficiency and excess—often supplement-driven—posing risk. GLP-1 receptor agonists were positioned as potential adjuncts in T1D amid obesity and suboptimal time-in-range.

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

AACE 2026 Recap: 5 Key Presentations to Know

Syed-Mohammed Jafri, MD, is a Gastroenterologist and Transplant Hepatologist at Henry Ford Hospital.

Reducing TPN Burden & Improving Quality of Life in Short Bowel Syndrome

Short bowel syndrome (SBS) remains a life-altering condition, often requiring lifelong reliance on parenteral support to maintain nutrition and hydration. While these therapies are lifesaving, new data presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, highlight a growing recognition among clinicians: the burden of total parenteral nutrition (TPN) extends far beyond clinical stabilization, with significant implications for safety, complications, and quality of life.

Patients with SBS dependent on parenteral support face substantial clinical and lifestyle challenges due to reduced intestinal function. TPN remains the cornerstone of management, but it is associated with a range of complications, including infections, thrombosis, and liver injury.

“We have been continuing to work with patients with short bowel syndrome now for over 15 years, and following these patients over time and really seeing the tough life that they lead,” Syed-Mohammed Jafri, MD, a gastroenterologist and transplant hepatologist at Henry Ford Hospital, told 

The data presented at DDW stemmed from a noninterventional, cross-sectional online survey conducted among HCPs in the US and Europe with ≥2 years of experience treating SBS patients and actively managing ≥1 patient. The survey assessed perceptions of TPN-related complications, clinical burden, and preferred outcome attributes for potential new therapies.

HCPs reported a high burden associated with TPN in patients with SBS dependent on parenteral support, with central line complications, fatigue, and decreased QoL being primary concerns. Reducing time on TPN was considered more impactful than volume reduction.

According to Jafri, the traditional focus on stabilization represents only the first phase of care, pointing to the need for a more comprehensive, long-term management strategy . While TPN can prevent malnutrition and stabilize electrolytes, it also introduces new risks that must be actively managed over time.

The study findings reinforce this perspective, showing that healthcare professionals prioritize minimizing complications and keeping patients out of the hospital. However, there is increasing awareness that treatment goals must extend beyond safety alone.

A central theme of the research is the importance of reducing the burden of TPN, particularly in terms of time. Nearly half of surveyed clinicians identified reducing the number of days per week on TPN as the most valuable outcome, followed by reducing hours per day. By comparison, fewer respondents prioritized reducing infusion volume.

This aligns closely with patient experiences. Many individuals require TPN infusions for up to 12 hours daily, limiting their ability to work, socialize, or leave home. As Jafri noted, patients often seek “a break” from therapy to regain a sense of normalcy in their daily lives .

Beyond quality of life, reducing time on TPN is also clinically beneficial. Fewer infusion hours and days may reduce exposure to central venous catheters, thereby lowering the risk of infections and thrombosis, 2 of the most serious complications identified in the study.

Implications for Clinical Practice and Future Research

These findings signal a shift in how clinicians approach SBS management. While maintaining stability and preventing hospitalizations remain critical, there is growing emphasis on balancing these goals with quality of life considerations. Actively pursuing strategies to wean patients from TPN when feasible is becoming an increasingly important aspect of care.

Looking ahead, there remains a need for innovative therapies that reduce dependence on parenteral support while maintaining nutritional adequacy. Advances in intestinal rehabilitation, improved delivery methods, and novel pharmacologic agents may all contribute to this goal.

Equally important is increasing awareness of SBS within the gastroenterology community. Early recognition and referral to specialized centers can help ensure patients receive comprehensive care tailored to both clinical and lifestyle needs.

Jafri SM, Harrison J, Kumpf V, et al. BURDEN OF TOTAL PARENTERAL NUTRITION FOR PATIENTS WITH SHORT BOWEL SYNDROME DEPENDENT ON PARENTERAL SUPPORT: HEALTHCARE PROFESSIONAL PERSPECTIVES ON RISKS, LIMITATIONS, AND TREATMENT PRIORITIES. Presented at Digestive Disease Week (DDW) 2026; Chicago, IL; May 2–5, 2026.

New research underscores the risks and daily burden of TPN in SBS, with focus shifting toward reducing dependence and complications.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Time Off TPN Emerging as Key Goal in Short Bowel Syndrome Care, With Syed-Mohammed Jafri, MD

Noreen Galaria, MD, is a board-certified and fellowship-trained dermatologist based in the Washington, D.C. area with over 20 years of experience. She is the founder of Inner Glow Vitamins and practices at Galaria Plastic Surgery & Dermatology.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Skin of Color Savvy: Misinformation, Holistic Dermatology, and Skin of Color, With Noreen Galaria, MD

, Noreen Galaria, MD, a board-certified dermatologist with more than 2 decades of experience, shared insights from her clinical practice and research interests, with a focus on holistic dermatologic care and considerations for patients with skin of color.

Galria runs a private practice and is also the founder of Inner Glow Vitamins, a line of dermatologist-developed skin supplements. Galaria described how her career evolved toward integrating conventional dermatology with naturopathic and internal approaches to skin health, particularly through the use of nutraceuticals and antioxidant-based strategies.

A key theme of the discussion centered on the importance of representation in dermatology. Galaria reflected on how practicing in different geographic regions shaped her awareness of disparities in training and patient care, particularly the limited exposure some clinicians have to diverse skin types. She emphasized how patients with skin of color often seek out physicians who they feel understand their unique concerns, which has informed both her clinical focus and research collaborations, including work addressing hair loss in women who wear head coverings. She highlighted the value of organizations like SOCS in fostering collaboration and advancing research that fills gaps in the literature.

Galaria also addressed ongoing challenges in dermatology, particularly the rise of misinformation driven by social media. While acknowledging that patients today are often more informed, she noted that information quality varies widely, requiring clinicians to guide patients toward evidence-based care tailored to individual skin types and conditions. This individualized approach was echoed in her discussion of treatment strategies, especially for conditions such as melasma and hyperpigmentation, where prevention and management require a more comprehensive understanding of factors like visible light exposure and internal oxidative stress.

The conversation explored the growing interest in internal photoprotection, with Galaria outlining how oral antioxidants, such as polypodium leucotomos and other compounds, can complement traditional sunscreens by addressing cellular damage pathways. She stressed that these approaches are adjunctive rather than replacements for sunscreen and highlighted their potential role in protecting against pigmentation, photoaging, and skin cancer. More broadly, she advocated for a layered, mechanism-based approach to skin health that combines topical and internal therapies.

Additional topics included physician wellness and interdisciplinary collaboration. Galaria emphasized the importance of sustainable self-care practices, such as habit stacking and prioritizing sleep, in addressing burnout. She also highlighted the role of dermatologists in recognizing systemic disease and working with specialists across disciplines to provide comprehensive care. Overall, the discussion underscored a shift toward more holistic, patient-centered dermatology that integrates science, lifestyle, and representation to improve outcomes.

To learn more about SOCS’s programs and initiatives, visit 

Editor’s note: This episode was summarized with the help of AI tools.

Podcasts

In this new Skin of Color Savvy podcast, Noreen Galeria, MD, discusses topics such as patient, misinformation, her career, and research on natural remedies.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Despite a relatively quiet month from the 

, the American College of Cardiology (ACC) Scientific Sessions 2026 more than made up for the lack of regulatory news with a continued series of key trial updates. From 

obstructive hypertrophic cardiomyopathy (oHCM)

, all aspects of cardiology saw significant forward movement during this conference. Additionally, updates to the ABCs of Cardiology and other guidelines in April continued the paradigm shift towards prevention that cardiology has embraced in recent months.

With so many trials reaching their endpoints, the editorial team at 

 has collected 7 of the most impactful headlines from the last 30 days below:


SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS


Presented by Joseph Rossano, MD, MS, co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, new data from the SCOUT-HCM trial have proven mavacamten’s efficacy in reducing left ventricular outflow in adolescent patients with oHCM compared with placebo. Additionally, of the 65 enrolled patients, adverse events occurred in only 18 in the mavacamten arm and 17 in the placebo arm, with only 2 serious adverse events in each group.

CORALreef AddOn: Enlicitide Outperforms Standard Hypercholesterolemia Drugs, With Ann Marie Navar, MD, PhD


The CORALreef AddOn trial has demonstrated enlicitide’s superior reduction of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. The trial compared enlicitide to bempedoic acid, ezetimibe, and a combination thereof – among patients with 

atherosclerotic cardiovascular disease (ASCVD)

, enlicitide saw a substantially higher LDL-C reduction than all 3 comparators. Ann Marie Navar, MD, PhD, discusses the results and their implication for an expected New Drug Application.


Self-Administered Etripamil for PSVT Has Minimal Blood Pressure, Heart Rate Effects, With Narendra Singh, MD


Etripamil nasal spray, recently approved for paroxysmal supraventricular tachycardia (PSVT), has minimal effects on blood pressure, despite a long history of calcium channel blockers leading to hypotension. Parts 1-3 of the NODE-301 trial, assessing heart rate and blood pressure changes in patients treated with a test dose of etripamil, revealed significantly lower blood pressure changes than other CCBs. Narendra Singh, MD, assistant professor at Mercer University Atlanta Campus, director of clinical research at NSC Cardiology, and co-author of NODE-301, spoke on the reassurance that this trial provides for clinicians prescribing etripamil.


Reviewing the Updated ABCs of Cardiovascular Disease Prevention, With Aaron Troy, MD, MPH


The ABCs of Cardiovascular Disease Prevention has recently undergone a major update, highlighting the PREVENT equations and Life’s Essential 8. Additionally, the document now includes 

, largely considered disease-focused areas rather than preventable conditions. Aaron Troy, MD, MPH, clinical research fellow at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, discusses the value of a more prevention-focused mindset in cardiovascular disease.

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc


Based on data presented at ACC 2026 by Mardi Gomberg-Maitland, MD, MSc, director of the pulmonary 

 program, chief clinical research officer at the Office of Clinical Research SMHS, and professor of medicine at George Washington University, sotatercept has successfully reduced pulmonary vascular resistance (PVR) in combined post- and pre-capillary pulmonary hypertension (CpcPH) heart failure with preserved ejection fraction (HFpEF). The ongoing CADENCE trial has already shown substantially greater PVR reductions compared to placebo at week 24.


Tonlamarsen Lowers Angiotensinogen, Mixed Results for Blood Pressure, With Luke Laffin, MD


An update from the Kardinal study, provided by Luke Laffin, MD, co-director of the Center for Blood Pressure Disorders and associate professor of medicine at the Cleveland Clinic, has shown that monthly tonlamarsen successfully lowered plasma angiotensinogen in patients with uncontrolled hypertension compared to a single dose. However, it led to no additional blood pressure reduction, indicating the need for further placebo-controlled trials to determine its efficacy in single doses or a multi-dose regimen.

Obicetrapib is Safe and Well-Tolerated in HeFH and ASCVD, With Stephen Nicholls, MD


A pooled safety analysis of the BROADWAY and BROOKLYN phase 3 trials has revealed the safety and tolerability of obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH) and ASCVD. Presented at ACC 2026 by Stephen Nicholls, MD, director of the Monash Victorian Heart Institute at Monash Health, these data indicated less new-onset diabetes, fewer adverse events, and less incidence of hypertension in patients treated with obicetrapib.

April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiomyopathy

Atherosclerotic Cardiovascular Disease

7 Cardiology Headlines You Missed in April 2026

Gil Melmed, MD, is affiliated with Cedars-Sinai Inflammatory Bowel Disease Center.

Gil Melmed, MD, breaks down real-world data showing risankizumab has the lowest switch rates in Crohn’s over 24 months, highlighting strong persistence vs other biologics.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Real-World Data Favor Risankizumab for Long-Term Persistence in Crohn's Disease

Anat Shoshani, PhD, professor at Reichman University and chief psychologist at Kai.ai.

Shoshani discusses RCT data showing AI reduces anxiety and improves well-being, with outcomes comparable to those of group therapy. 

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Conversational AI for Anxiety Matches Group Therapy Outcomes, With Anat Shoshani, PhD

In this segment from the April episode of The Medical Sisterhood podcast, the speakers discussed simple ways for physicians to get involved in community service without feeling overwhelmed.

How to Get Involved in Community Service in Dermatology, With Elizabeth Kiracofe, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Volixibat reduced cholestatic pruritus in phase 2b primary sclerosing cholangitis data, with diarrhea and liver test elevations reported.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Volixibat Improves Pruritus in Phase 2b PSC Trial, With GI and Liver Safety Signals

Ariann Chelli, LCSW, LCADC, MBA, is the clinical director at Desert Hope Treatment Center, an American Addiction Centers facility.

Without FDA-approved medications or standardized detox protocols, clinicians face unique challenges treating methamphetamine addiction.

Addiction

Addiction medicine condition center page, resources on the topics of medical news and expert insight into clinical addiction can be found. Content includes articles, interviews, videos, podcasts, and breaking news on addiction therapy research, treatment, and drug development.

Treating Methamphetamine Use Disorder Without FDA-Approved Medications

Joseph Murray, MD, is a gastroenterologist at Mayo Clinic.

Murray breaks down what gastroenterologists need to know about celiac disease diagnosis and management.

Confronting Unmet Needs in Celiac Disease, With Joseph Murray, MD

Marla Dubinsky, MD, is chief of the division of pediatric gastroenterology and nutrition and co-director of the Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children's Hospital, Icahn School of Medicine.

Marla Dubinsky, MD, explains LIBERTY post hoc data showing SC infliximab 240 mg recaptured clinical response within 8 weeks in CD and UC patients following a drug holiday.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Subcutaneous Infliximab Recaptures Disease Control After Treatment Interruption in IBD

Laurie Keefer, PhD, is a clinical health psychologist and professor of medicine at Icahn School of Medicine at Mount Sinai.

Laurie Keefer, PhD, makes the case for integrating mental health, social determinants, and brain-gut behavior therapies into routine GI care.

Rethinking Gut Health: Social Determinants, Mental Health, and Brain-Gut Therapies

Anjali Byale, MD, is a fellow at West Virginia University School of Medicine.

Anjali Byale, MD, reviews data supporting EUS-guided procedures as first-line options for high-risk patients with cholecystitis or malignant gastric outlet obstruction.

EUS-Guided Procedures Outperform Traditional Interventions for High-Risk GI Patients

Sobia Laique, MD, is a gastroenterologist and transplant hepatologist at Cleveland Clinic.

New paired biopsy data show histologic regression after metabolic bariatric surgery in compensated MASH patients, challenging the irreversibility of cirrhosis.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Latest News

5 Nephrology Headlines You Missed in April 2026

AACE 2026 Recap: 5 Key Presentations to Know

Time Off TPN Emerging as Key Goal in Short Bowel Syndrome Care, With Syed-Mohammed Jafri, MD

Skin of Color Savvy: Misinformation, Holistic Dermatology, and Skin of Color, With Noreen Galaria, MD

7 Cardiology Headlines You Missed in April 2026